Accelerate to discover

Back to filter

Related topics

Webinar: A simple Migration/Invasion workflow using IncuCyte Live-cell analysis system

Sartorius

Jan 27, 2021

 Cell migration and invasion, or cell motility, play a role in many normal and pathological processes including immune...

Webinar : meet the Cytek's new cFluor reagents

Cytek Biosciences

Jan 25, 2021

Cytek Biosciences has already redefined what is possible in flow cytometry. The new Cytek cFluor family of reagents...

STAT Protein Phosphorylation in CD4+ T Cells using the CellStream flow cytometer

Luminex

Jan 21, 2021

Cytokine-induced protein phosphorylation is a key cell signaling event within the immune system that modulates diverse...

Introducing Cytek cFluor, 14 Colors Immunoprofiling Kit

Cytek Biosciences

Jan 19, 2021

Cytek cFluor Immunoprofiling Kit allows for the identification of helper T cells, cytotoxic T cells, B cells, NK cells...

Jan 27, 2021

A Glimpse on physiological monitoring for the in vivo SKYSCAN Systems

Bruker Biospin

Jan 14, 2021

This past year has proven once again that in vivo imaging is an important aspect in the microCT world. For longitudinal...

Cytek full Spectrum flow Cytometry webinar: Part II – panel design and troubleshooting

Cytek Biosciences

Jan 11, 2021

In this session, we will continue to look at full spectrum flow cytometry and look at considerations for fluorescence...

CQ1 webinar : optimizing high-content imaging of 3D models for drug discovery

Yokogawa

Jan 7, 2021

In vitro spheroid models are fast becoming the de facto standard for drug discovery applications, largely due to their...

Jan 27, 2021

IncuCyte for in-vitro analysis of SARS-CoV-2 vaccine candidate

Sartorius

Jan 4, 2021

Watch this video to learn how researcher at Humane Genomics are utilizing the Incucyte platform for the in-vitro...

Show all topics (10)

Preclinical cardiac safety assesment

Mar 22, 2016

Over the last two decades, a number of blockbuster drugs have been withdrawn or have incurred safety warnings by regulatory agencies due to adverse cardiac effects. In addition, lead compounds or drug candidates are frequently terminated at late stages of drug development due to cardiac safety concerns. Both of these factors can significantly impact the overall cost of drug discovery; consequently, pharmaceutical companies and regulatory agencies have implemented procedures to address these issues.

Most, if not all, in vitro assay systems for cardiac safety are designed to screen for surrogates of arrhythmia, such as hERG channel interaction, rather than arrhythmia itself. Assays designed to screen for compounds that may affect repolarization and induce arrhythmia in the context of the whole heart or heart tissue are not implemented until much later in drug development. These include sophisticated, technically demanding, lowthroughput, and costly procedures such as the Purkinje fiber assay, ventricular wedge assay, and the Langendorff whole heart assay, or telemetry experiments in live and anesthetized animals. The field of preclinical cardiac safety can certainly benefit from an assay system that allows for integrated assessment of compound action on ion channel and non-ion channel targets involved in cardiac excitation-contraction coupling.

The RTCA Cardio Instrument in conjunction with iCell Cardiomyocytes comprises an assay system providing integrated assessment of compound action on multiple targets involved in heart function. This assay system can sensitively and quantitatively detect the effect of compounds on the major ion channels involved in heart function, namely calcium, sodium, and potassium channels. Another major advantage of the assay system is the time resolution. The RTCA Cardio Instrument has a data acquisition rate of 12.5 ms per well of a 96-well plate and can be used simultaneously to monitor acute and chronic drug effects up to days and weeks. The utility of the time-dependent monitoring of compound action on cardiomyocytes can be demonstrated by testing compounds that acutely and directly block hERG channels (E4031, cisapride, etc.) and compounds that interfere with protein trafficking (pentamidine) in a sub-chronic manner. The RTCA Cardio Instrument is able to detect the effects of these compounds on the beating rate and duration of iCell Cardiomyocytes.

The xCELLigence System RTCA Cardio Instrument, in conjunction with iCell Cardiomyocytes, represents a physiologically relevant and predictive assay system for preclinical cardio-safety assessment of lead compounds. The features of this assay system, including time resolution, dynamic monitoring of mechanical beating activity of cardiomyocytes, and 96-well throughput, will surely provide additional mechanistic and toxicity information for compound action on the heart.

Application
Product news

Related technologies: Real-time, label free cell analysis

Brand profile

Agilent technologies

Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.

Related products

Cardio Instrument is a high-resolution system for label-free-dual-mode monitoring of cardiomyocyte and cardiotoxicity testing

show detail

The new CardioECR system combines impedance and Multi Electrode Array (MEA) technology with a pacing function

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey